Pharmacological treatment of negative symptoms in schizophrenia; research and practice;Medicamenteuze interventie bij negatieve symptomen bij patiënten met schizofrenie

Tijdschrift voor Psychiatrie

Volumn 52, Issue 9, 2010, Pages 627-637

  Jiawan, V C R ^a   Arends, J ^b   Slooff, C J ^c   Knegtering, H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Afdeling Psychosecircuit   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Medication; Negative symptoms; Schizophrenia

Indexed keywords

CLOZAPINE; GLUTAMIC ACID; HALOPERIDOL; NEUROLEPTIC AGENT; RISPERIDONE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG MECHANISM; HUMAN; META ANALYSIS; NEGATIVE SYNDROME; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEROTONINERGIC SYSTEM; SYSTEMATIC REVIEW; META ANALYSIS (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; HUMANS; META-ANALYSIS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 77956653559     PISSN: 03037339     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Afshar, A., Noorbala, A.A., Nejatisafa, A.A., e.a. (2008a). Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind, placebo-controlled study. Human psychopharmacology, 23, 79-86.
2. Afshar, A., Roohafza, H., Mousavi, G., e.a. (2008b). Topiramate add-on treatment in schizophrenia: a randomized, double-blind, and placebo-controlled clinical trial. Journal of clinical psychopharmacology doi:10.1177/ 0269881108089816
3. Akhondzadeh, S., Mohammadi, M.R., Amini-Nooshabadi, H., e.a. (1999). Cyproheptadine in treatment of chronic schizophrenia: a double-blind, placebo-controlled study. Journal of clinical pharmacy and therapeutics, 24, 49-52.
4. Akhondzadeh, S., Nejatisafa, A.A., Amini-Nooshabadi, H., e.a. (2003). Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial. Progress in neuro-psychopharmacolooy & biological psychiatry, 27, 1007-1012.
5. Akhondzadeh, S., Mohammadi, N., Noroozian, M., e.a. (2008a). Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial. Schizophrenia Research, doi:10.1016/j.schres.2008.08.004.
6. Akhondzadeh, S., Malek-Hosseini, M., Ghoreishi, A., e.a. (2008b). Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: A double-blind randomised placebo-controlled trial. Progress in Neuro-Psychopharmacology & Biological Psychiatry, doi:10.1016/j.pnpbp.2008. 08.020.
7. Andreasen, N.C. (1989). Scale for the assessment of negative symptoms. British Journal of Psychiatry, 155, 53-58.
8. Bergemann, N., Mundt, C., Parzer, P., e.a. (2005). Estrogen as an adjuvant therapy to antipsychotics does not prevent relapse in women suffering from schizophrenia: results of a placebo-controlled double-blind study. Schizophrenia research, 74, 125-134.
9. Berk, M., Ichim, C., & Brook, S. (2001). Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. International clinical psychopharmacology, 16, 87-92. (Pubitemid 32171833)
10. Berk, M., Copolov, D., Dean, O., e.a. (2008). N-acetyl cysteine as glutathione precursor for schizophrenia- a double-blind, randomized, placebo-controlled trial. Biological psychiatry doi:10.1016/j.biopsych.2008.03. 004.
11. Berk, M., Gama, C.S., Sundram, S., e.a. (2009). Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial. Human psychofarmacology, 24, 233-238.
12. Bodkin, J.A., Siris, S.G., Bermanzohn, P.C., e.a. (2005). Double-blind, placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia. The American journal of psychiatry, 162, 388-390.
13. Breier, A. (1995). Serotonin, schizophrenia and antipsychotic drug action. Schizophrenia research, 14, 187-202.
14. Buchanan, R.W., Davis, M., Goff, D., e.a. (2005). A Summary of the FDA-NIMH-MATRICS Workshop on Clinical Trial Design for Neurocognitive Drugs for Schizophrenia. Schizophrenia research, 31, 5-19.
15. Buckman, T.D., Kling, A., Sutphin, M.S., e.a. (1990). Platelet glutathione peroxidase and monoamine oxidase activity in schizophrenics with CT scan abnormalities: relation to psychosocial variables. Psychiatry Research, 31, 1-14
16. Carpenter, W.T., Jr., Breier, A., Buchanan, R.W., e.a. (2000). Mazindol treatment of negative symptoms. Neuropsychopharmacology 23: 365-374.
17. Coyle, J.T., Tsai, G., & Goff, D.C. (2002). Ionotropic glutamate receptors as therapeutic targets in schizophrenia. Current drug targets. CNS and neurological disorders, 1, 183-189.
18. Doruk, A., Uzun, O., & Ozsahin, A. (2008) A placebo-controlled study of the extract of Ginkgo Biloba added to clozapine in patients with treatment resistant schizophrenia. International clinical psychopharmacology, 23, 223-227.
19. Duinkerke, S.J., Botter, P.A., Jansen, A.A., e.a. (1993). Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial. The British journal of psychiatry, 163, 451-455.
20. Duisterwinkel G., Bosker F.J., Scholte-Stalenhoef A.N., e.a. (2008). Antipsychotic augmentation strategies to ameliorate negative and cognitive symptoms in schizophrenia. Central Nervous System Agents in Medical Chemistry, 8, 10-25.
21. Goff, D.C., Keefe, R., Citrome, L., e.a. (2007). Lamotrigine as add-on therapy in schizophrenia. Journal of clinical psychopharmacology, 27, 582-589.
22. Goff, D.C., Cather, C., Gottlieb, J.D., e.a. (2008). Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: An exploratory study Schizophrenia Research, doi:10.1016/j.schres.2008.08.012.
23. Halbreich, U., & Kahn, L.S. (2003). Hormonal aspects of schizophrenias: an overview. Psychoneuroendocrinology, 28 Suppl 2, 1-16.
24. Joffe, G., Terevnikov, V., Joffe, M., e.a. (2009). Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: A double-blind, randomized, placebo-controlled trial. Schizophrenia research, 108, 245-251.
25. Javitt, D.C. (2006). Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients. Current opinion in psychiatry, 19, 151-157.
26. Jungerman, T., Rabinowitz, D., & Klein, E. (1999). Deprenyl augmentation for treating negative symptoms of schizophrenia: a double-blind, controlled study. Journal of clinical psychopharmacology, 19, 522-525.
27. Kay, S.R., Fiszbein, A., & Opler, L.A. (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13, 261-276. (Pubitemid 18039085)
28. Kremer, I., Vass, A., Gorelik, I., e.a. (2004). Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. Biological psychiatry, 56, 441-446.
29. Kulkarni, J., Riedel, A., de Castella, A.R., e.a. (2001). Estrogen - a potential treatment for schizophrenia. Schizophrenia research, 48, 137-144.
30. Kulkarni, J., Riedel, A., de Castella, A.R., e.a. (2002). A clinical trial of adjunctive oestrogen treatment in women with schizophrenia. Archives of women's mental health, 5, 99-104.
31. Lane, H.Y., Chang, Y.C., Liu, Y.C., e.a. (2005). Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Archives of general psychiatry, 62, 1196-1204.
32. Lane, H.Y., Huang, C.L., Wu, P.L., e.a. (2006). Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biological psychiatry, 60, 645-649.
33. Leucht, S., Pitschel-Walz, G., Abraham, D., e.a. (1999). Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophrenia Research, 35, 51-68.
34. Leucht, S., Corves, C., Arbter, D., e.a. (2009). Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet, 373, 31-41.
35. Loonen, A.J.M. (2004). Het beweeglijke brein. (p. 67). Badhoevedorp: Mension.
36. Louza, M.R., Marques, A.P., Elkis, H., e.a. (2004). Conjugated estrogens as adjuvant therapy in the treatment of acute schizophrenia: a double-blind study. Schizophrenia Research, 66, 97-100.
37. Luo, H.C., Shen, Y.C., Meng, F.Q. (1997). Therapeutic effect of shuxuening combining neuroleptics for the treatment of chronic schizophrenia - a double blind study. Zhongguo Zhong Xi Yi Jie He Za Zhi, 17, 139-142.
38. Maas, J.W., Miller, A.L., Tekell, J.L., e.a. (1995). Clonidine plus haloperidol in the treatment of schizophrenia/psychosis. Journal of clinical psychopharmacology, 15, 361-364.
39. Mahadik, S.P., Evans, D., & Lal, H. (2001). Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry, 25, 463-493. (Pubitemid 32391533)
40. Moller, H.J. (2007). Clinical evaluation of negative symptoms in schizophrenia. European psychiatry, 22, 380-386.
41. Nachshoni, T., Levin, Y., Levy, A., e.a. (1994). A double-blind trial of carbamazepine in negative symptom schizophrenia. Biological psychiatry, 35, 22-26.
42. Noorbala, A.A., Akhondzadeh, S., Davari-Ashtiani, R., e.a. (1999). Piracetam in the treatment of schizophrenia: implications for the glutamate hypothesis of schizophrenia. Journal of clinical pharmacy and therapeutics, 24, 369-374.
43. Overall J.E. (1988). The Brief Psychiatric Rating Scale (BPRS). Recent developments in ascertainment and scaling. Psychopharmacology Bulletin, 24, 909-923.
44. Premkumar, T.S., & Pick, J. (2006). Lamotrigine for schizophrenia. Cochrane Database of Systematic Reviews, 4, CD005962.
45. Pierre, J.M., John, H., Peloian, M.A., e.a. (2007). A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia. The Journal of clinical psychiatry, 68, 705-710
46. Riecher-Rössler, A. (2002). Oestrogen effects in schizophrenia and their potential therapeutic implications - review. Archives of women's mental health, 5, 111-118.
47. Ritsner, M.S., Gibel, A., Ratner, Y., e.a. (2006). Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. Journal of clinical psychopharmacology, 26, 495-499.
48. Ross, C.A., Margolis, R.L., Reading, S.A., e.a. (2006). Neurobiology of schizophrenia. Neuron, 52, 139-153.
49. Sepehry, A.A., Potvin, S., Elie, R., e.a. (2007). Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis. The Journal of clinical psychiatry, 68, 604-610.
50. Sevy, S., Rosenthal, M.H., Alvir, J., e.a. (2005). Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications. The Journal of clinical psychiatry, 66, 839-843.
51. Shiloh, R., Zemishlany, Z., Aizenberg, D., e.a. (2002). Mianserin or placebo as adjuncts to typical antipsychotics in resistant schizophrenia. International clinical psychopharmacology, 17, 59-64.
52. Silver, H., Blacker, M., Weller, M.P., e.a. (1991). Treatment of chronic schizophrenia with cyproheptadine: a double-blind placebo-controlled study. Biological psychiatry, 30, 523-525.
53. Strous, R.D. (2005). Dehydroepiandrosterone (DHEA) augmentation in the management of schizophrenia symptomatology. Essential psychopharmacology, 6, 141-147.
54. Strous, R.D., Maayan, R., Lapidus, R., e.a. (2003). Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Archives of general psychiatry, 60, 133-141.
55. Strous, R.D., Stryjer, R., Maayan, R., e.a. (2007). Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHFA) administration in olanzapine treated schizophrenia patients: A randomized, double-blind placebo controlled trial. Psychoneuroendocrinology, 32, 96-105.
56. Tiihonen, J., Hallikainen, T., Ryynanen, O.P., e.a. (2003). Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biological psychiatry, 54, 1241-1248.
57. Tiihonen, J., Halonen, P., Wahlbeck, K., e.a. (2005). Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. The Journal of clinical psychiatry, 66, 1012-1015.
58. Tiihonen, J., Wahlbeck, K., Kiviniemi, V. (2009). The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. Schizophrenia Research, 109, 10-14.
59. Tsai, G., Lane, H.Y., Yang, P., e.a. (2004). Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biological psychiatry, 55, 452-456.
60. Tuominen, H.J., Tiihonen, J., & Wahlbeck, K. (2005). Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophrenia Research, 72, 225-234. (Pubitemid 39550993)
61. Wassef, A.A., Dott, S.G., Harris, A., e.a. (2000). Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia. Journal of clinical psychopharmacology, 20, 357-361.
62. Young-Hoon, K., Young-Min, L., Sung-Won, J., e.a. (2008). Short-term testosterone augmentation in male schizophrenics. Journal of clinical psychopharmacology, 28, 375-383.
63. Zhang, X.Y., Zhou, D.F., Zhang, P.Y., e.a. (2001). A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia. The Journal of clinical psychiatry, 62, 878-883.
64. Zoccali, R., Muscatello, M.R., Cedro, C., e.a. (2004). The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study. International clinical psychopharmacology, 19, 71-76. (Pubitemid 38324586)
65. Zoccali, R., Muscatello, M.R., Bruno, A., e.a. (2007). The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: a double-blind, placebo-controlled study. Schizophrenia Research, 93, 109-116.